Clinical trial
A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer
NCT00519285 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2007
- Completion date
- April 30, 2012
- Enrollment
- 1,224 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.